DATE : 16-03-14 14:34
|
Everolimus-eluting versus sirolimus-eluting coronary stents in patients with and without diabetes mellitus.
|
|
|
WRITER :
stent
 HIT : 1,365
|
 C162._EuroIntervention._2014;10_1_74-82..PDF (1.0M) [0] DATE : 2016-03-14 14:34:19 |
C162. Kang SH, Park KH, Ahn HS, Park KW, Hong YJ, Koo BK, Jeong MH, Kim HS; Everolimus-eluting versus sirolimus-eluting coronary stents in patients with and without diabetes mellitus. EuroIntervention. 2014;10(1)74-82.
(Abstract)
AIMS:
Patients with diabetes mellitus have a higher risk of adverse events after percutaneous coronary intervention (PCI). This study aimed to elucidate the relative efficacy of everolimus-eluting stents (EES) versus sirolimus-eluting stents (SES) according to diabetic status.
METHODS AND RESULTS:
Data from the EXCELLENT randomised trial and registry were pooled in a per protocol analysis manner. The primary endpoint was target lesion failure (TLF), a composite of cardiac death, target vessel-related myocardial infarction, or target vessel revascularisation. Among a total of 6,524 patients, 2,404 (36.8%) had diabetes mellitus. Patients with diabetes were shown to have a higher rate of TLF after PCI, which was mainly driven by differences in cardiac death and myocardial infarction, while the rate of repeat revascularisation and stent thrombosis did not differ significantly. TLF occurred at a similar rate between patients treated with EES versus SES in each subgroup stratified by diabetic status (interaction p=0.384). In addition, no significant interactions were present with regard to any pre-specified clinical endpoints. The results were corroborated by analysis with inverse probability of treatment weighting (interaction p=0.329). We also found that insulin-dependent diabetes imposed an even greater risk of TLF on patients treated with PCI.
CONCLUSIONS:
Despite the recent advances in drug-eluting stent technology, diabetic patients are still at higher risk of adverse clinical events after PCI than those without diabetes mellitus. Whether a patient was treated with EES or SES had no significant interaction with diabetic status in terms of clinical outcome after PCI.
|
|
